【드래곤 스포츠】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 뉴스 : 안구정화

로그인

글쓰기

[IT뉴스]Samyang Biopharm Hits Second Straight Upper-Limit Gain [K-Bio Pulse]

온카뱅크관리자

2025-12-03 10:47:33

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
 <section dmcf-sid="2T4pPWhDsx">
 <div contents-hash="a1589764717af3a793c7afc4b2839cc0f6466cd4431c719405692feb58aa4d77" dmcf-pid="VuaPAz3GDQ" dmcf-ptype="general">
 <div>
 This article was released as Pharm Edaily Premium Content on November 26, 2025, at 10:44 AM.
 </div>
 </div>
 [Seungkwon Kim, Edaily Reporter] On the 25th, shares of companies in Korea’s pharmaceutical, biotech and healthcare sector with strong clinical trial momentum and expectations for overseas partnership deals jumped sharply. Samyang Biopharm, C&amp;R Research and Abion were the main movers, with Samyang Biopharm in particular locking in its second consecutive upper-limit gain following a spin-off.
 Samyang Biopharm closed at 39,250 won, up 29.97% from the previous session, according to KG Zeroin MP Doctor. The stock has now hit the daily upper price limit for two straight sessions after being relisted the previous day through a spin-off from Samyang Holdings, the holding company of Samyang Group. It had finished the prior session at a price 29% above its opening level of 23,250 won. The rally is seen as driven by expectations that the spin-off and separate listing will allow the market to better recognize the company’s technological capabilities and growth potential.
 Samyang Biopharm is an independent company dedicated to pharmaceutical and biotech businesses. In 1993, it became the first company in Korea to successfully develop biodegradable surgical sutures and currently maintains the No. 1 share of the global surgical suture thread market.
 <figure class="figure_frm origin_fig" contents-hash="ad85ee0463016a5c3353799fb2c14c0160ba08a71fa4ecf75afc8b4808bf2a8b" dmcf-pid="6BcRDKu5r4" dmcf-ptype="figure">
 <img class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202512/03/Edaily/20251203104651220emtu.png" data-org-width="761" dmcf-mid="KP2F4vOcwR" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202512/03/Edaily/20251203104651220emtu.png" width="658">
 </figure>
 The company has also strengthened its oncology-focused drug business, building a portfolio of anticancer therapies covering seven solid tumors and five hematologic cancers. In particular, it developed Genexol, a generic version of Taxol, the paclitaxel-based anticancer drug created by U.S.-based Bristol Myers Squibb (BMS). Genexol is used to treat lung, breast and ovarian cancers and accounts for more than half of the domestic market for paclitaxel-based anticancer drugs. Recently, the company completed a cytotoxic injectable anticancer drug plant with annual capacity of 5 million vials and obtained GMP certification in Japan and Europe.
 A key area of future growth is new drug development based on its SENS platform. SENS is a platform that Samyang developed last year after 30 years of research; it accurately delivers genetic materials such as messenger RNA (mRNA) and small interfering RNA (siRNA) to specific cells. For mRNA therapeutics, the core technology lies in the “delivery vehicle” that safely transports genetic information into cells.
 Among the candidates being developed using SENS, the prophylactic vaccine SYP-2246 and the anticancer drug SYP-2135 are representative assets. SYP-2135 utilizes an mRNA delivery technology in-licensed from LG Chem. The company also plans to strengthen its global competitiveness with a portfolio centered on high-value-added bio products such as biodegradable surgical sutures, gene delivery carriers and anticancer drugs.
 A Samyang Biopharm official said, “Now that we are listed as a separate company, our business performance, growth potential and technology can be evaluated independently through public disclosures,” adding, “We plan to enhance corporate value based on a portfolio centered on specialty, high-functionality products such as biodegradable surgical sutures, gene delivery carriers and anticancer drugs.”
 C&amp;R Research also hit the daily upper price limit, closing at 1,102 won, up 254 won, or 29.95%, from the previous session. Despite a short-term slowdown in earnings, the company is seen as maintaining medium- to long-term growth potential on the back of a sizable order backlog of around 150 billion won and sound cash holdings of 7 billion won.
 In particular, buying interest appears to have been fueled by news that IMGT’s IMD10, a focused ultrasound system for treating pancreatic cancer, has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). This IDE represents C&amp;R Research’s first such FDA approval achieved by leading the overall clinical trial program together with its U.S. subsidiary, C&amp;R US, and is being viewed as a meaningful milestone in overcoming barriers for Korean medical devices to enter global clinical trials.
 IMD10 had already been designated a Breakthrough Device by the FDA in February, recognizing its technological strengths and clinical potential. With the latest IDE approval, clinical trials in the United States can formally begin, setting in motion core procedures toward global commercialization.
 C&amp;R Research plans to oversee subsequent steps, including U.S. clinical trial operations, data management and statistical analysis, and support for FDA marketing approval applications such as PMA and 510(k) filings. Through these efforts, the company aims to accelerate the early commercialization and global market rollout of IMD10 and strengthen the practical foundation needed for Korean medical device firms to expand overseas.
 A C&amp;R Research official said, “We will successfully complete the pivotal U.S. clinical trial so that IMD10 can overcome the limitations of existing treatments and provide a new therapeutic option for pancreatic cancer patients worldwide.”
 <figure class="figure_frm origin_fig" contents-hash="766ee4ef1c65ad60c7ba4a51d761c1710a04057031398ce3d19342eaa6b9f557" dmcf-pid="Zk0TuDNdr7" dmcf-ptype="figure">
 <img class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202512/03/Edaily/20251203104652470njex.png" data-org-width="800" dmcf-mid="9cNQcq0HrM" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202512/03/Edaily/20251203104652470njex.png" width="658">
 </figure>
 Abion’s share price rose on the back of steady progress in its rights offering and expectations for future partnership agreements. Abion closed at 5,150 won, up about 15% on the day.
 The company said that existing shareholders subscribed to 72.34% of its ongoing rights offering, which consists of a shareholder allocation followed by a public offering of forfeited shares. Including oversubscription, a total of 14,902,876 shares were taken up, leaving 5,697,124 shares to be offered in the public tranche.
 Alongside the paid-in capital increase, Abion will also carry out a bonus issue at a ratio of 0.8 new share per existing share to enhance shareholder value. The record date for the bonus shares is Dec. 2.
 “With the existing shareholder subscription now stably completed, we will proceed with the remaining public offering process without a hitch,” a company official said. “The funds raised will be used to accelerate clinical development of our key pipelines and to strengthen our financial structure, thereby reinforcing our growth foundation.”
 Investors are also looking ahead to concrete deal terms with Abion’s partners. The company’s main pipelines include ABN401, a treatment for non-small cell lung cancer, and ABN202, an anticancer immunotherapy. In June, Abion signed a global license-out and co-development agreement for ABN501 with a U.S. biotech company.
 While detailed terms of the deal cannot be disclosed under a confidentiality agreement, the company said it is in close communication with its partner and has high expectations for future milestone and royalty income.
 김승권 (peace@edaily.co.kr) 
 </section> 
 </div> 
 Copyright © 이데일리. 무단전재 및 재배포 금지.

댓글 총 0개

이번주 포인트랭킹

매주 일요일 밤 0시에 랭킹을 초기화합니다.

14,000상품권
23,000상품권
32,000상품권

업체홍보/구인 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기